• AAPL 169.3
  • TSLA 168.29
  • AMZN 179.62
  • MSFT 406.32
  • INTC 31.88
  • EURUSD 1.0705
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. XETRA /
  3. ACT.XETRA

AlzChem Group AG (ACT XETRA) stock market data APIs

€45.97 0.17(0.4%) as of April 26, 2024

AlzChem Group AG Financial Data Overview

45.5
45.97
-
46.08
44.91
17.55-48
466 M
13.4706
10 176 K
546 M
0.59
0.0262
1.097
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ACT',
Type: 'Common Stock',
Name: 'AlzChem Group AG',
Exchange: 'XETRA',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Germany',
CountryISO: 'DE',
OpenFigi: NULL,
ISIN: 'DE000A2YNT30',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Basic Materials',
Industry: 'Specialty Chemicals',
}

AlzChem Group AG Fundamental Data is available in our Financial Data APIs

  • Net Revenue 546 M
  • EBITDA 77 075 K
  • Earnings Per Share 3.4
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get AlzChem Group AG Earnings via APIs

  • Latest Release 2022-10-26
  • EPS/Forecast 0.35

Get AlzChem Group AG End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get AlzChem Group AG latest news via APIs

AlzChem Group Full Year 2022 Earnings: EPS Beats Expectations

AlzChem Group (ETR:ACT) Full Year 2022 Results Key Financial Results Revenue: €566.4m (up 32% from FY 2021). Net income: €30.1m (up 8.9% from FY 2021). Profit margin: 5.3% (down from 6.4% in FY ...
  • ALZCHEM GROUP
  • FY
  • PROFIT MARGIN
  • REVENUE GROWTH

Here's a Multibillion-Dollar Market for Johnson & Johnson

In this video from Motley Fool Live, recorded on March 22, Fool.com contributors Brian Orelli and Keith Speights discuss the prospects for Ponvory, which may be narrow because of its late entry into the space. Brian Orelli: Johnson & Johnson gained FDA approval for Ponvory.
  • ACTELION
  • BLOODSTREAM
  • BRIAN ORELLI
  • BRISTOL MYERS SQUIBB
  • FOOD AND DRUG ADMINISTRATION
  • JOHNSON & JOHNSON
  • KEITH SPEIGHTS
  • MOTLEY FOOL
  • MULTIPLE SCLEROSIS
  • PONVORY
Do you have any questions?
support@eodhistoricaldata.com